<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363021</url>
  </required_header>
  <id_info>
    <org_study_id>PREVASCLERO (29BRC20.0080)</org_study_id>
    <nct_id>NCT04363021</nct_id>
  </id_info>
  <brief_title>Is a History of Pre-eclampsia a Risk Factor for Vascular Phenotype in Women With Systemic Sclerosis?</brief_title>
  <acronym>PREVASCLERO</acronym>
  <official_title>Is a History of Pre-eclampsia Before Systemic Sclerosis Onset a Risk Factor for Vascular Phenotype in Women With Systemic Sclerosis?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      Pre-eclampsia, defined by the association of an arterial hypertension and significant
      proteinuria after 20 weeks of gestation, complicates 1 to 2% of pregnancies in France. Its
      pathophysiology involves angiogenesis impairment, upregulated maternal systemic inflammatory
      response, activation of oxidative stress and endothelial dysfunction.

      In a recent Danish nation-wide cohort study, pre-eclampsia was associated with a 69%
      increased risk of later developing scleroderma.

      Type of study: prospective observational case-control study. Primary objective of the study:
      to determine if a history of pre-eclampsia before systemic sclerosis diagnosis is an
      independent risk factor for vascular phenotype in sclerodermic women.

      Secondary objective: to describe all risk factors for vascular phenotype in sclerodermic
      women with a previous pregnancy longer than 6 months before scleroderma diagnosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background :

      Pre-eclampsia is defined by the association of an arterial hypertension and significant
      proteinuria after 20 weeks of gestation. It complicates 1 to 2% of pregnancies in France. Its
      pathophysiology involves angiogenesis impairment, upregulated maternal systemic inflammatory
      response, activation of oxidative stress and endothelial dysfunction.

      In a recent Danish nation-wide cohort study, pre-eclampsia was associated with a 69%
      increased risk of later developing scleroderma. A case-control study on 103 women with
      systemic sclerosis compared to 103 control women had already found an increased incidence of
      previous vasculoplacental disorders in women with systemic sclerosis. Women developed
      systemic sclerosis on average 27 years after their first pregnancy.

      Primary objective of the study : to determine if a history of pre-eclampsia before systemic
      sclerosis diagnosis is an independent risk factor for vascular phenotype in sclerodermic
      women.

      Secondary objective: to describe all risk factors for vascular phenotype in sclerodermic
      women with a previous pregnancy longer than 6 months before scleroderma diagnosis.

      Conduct of the study:

      It is a prospective observational case-control study. Cases will be defined as women with
      systemic sclerosis, specific vascular complications (digital ulcers, specific cardiac
      involvement of systemic sclerosis including pulmonary arterial hypertension, renal crisis)
      and with a previous pregnancy longer than 6 months before systemic sclerosis diagnosis.

      Controls will be defined as women with systemic sclerosis, no specific vascular complication
      and with a previous pregnancy longer than 6 months before systemic sclerosis diagnosis.

      Conduct of the study:

      A self-administered &quot; pregnancy &quot; questionnaire will be given to each women with systemic
      sclerosis of the cohort group during the annual follow-up consultation. A case report form
      will be completed at the same time by the physician in charge of the patient.

      The &quot; pregnancy &quot; questionnaire will consist of two parts :

        -  A part &quot; pre-eclampsia questionnaire &quot;, derived from the translation in French of a
           questionnaire validated in English.

        -  A second part with additional questions on pregnancies. The duration of participation to
           the study will be of one day. The duration of the inclusion period will be of 24 months.
           Needed number of patients : 340 women, i.e. 170 in each group.

      Perspectives of the study :

      If this study demonstrates that a previous pre-eclampsia is an independent risk factor for
      vascular phenotype in women with systemic sclerosis, it will be mandatory to look for a
      history of pre-eclampsia in women at the time of systemic sclerosis diagnosis. Besides, the
      women with a history of pre-eclampsia should be monitored more frequently for vascular
      complications related to systemic sclerosis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>History of pre-eclampsia before systemic sclerosis diagnosis</measure>
    <time_frame>Inclusion (Day 0)</time_frame>
    <description>Primary outcome will be evaluated by the proportion of women with a history of pre-eclampsia before systemic sclerosis diagnosis in each group. Primary judgement criterion will be the response of a woman to the &quot; pre-eclampsia questionnaire &quot;. The aim is to determine if a history of pre-eclampsia before systemic sclerosis diagnosis is an independent prognostic factor for vascular phenotype in sclerodermic women.
Primary judgement criterion: Responses of the women to the &quot; pre-eclampsia questionnaire &quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk factors for vascular phenotype in sclerodermic women with a previous pregnancy longer than 6 months</measure>
    <time_frame>Inclusion (Day 0)</time_frame>
    <description>Secondary outcomes will be evaluated by the proportion of women with chronic hypertension, diffuse systemic sclerosis, disease duration &gt; 5 years, anti-centromere antibodies, anti-Scl70 antibodies, antiphospholipid antibodies, antiphospholipid syndrome, interstitial lung disease, and tobacco use, in each group, mean age at systemic sclerosis diagnosis in each group. Secondary judgement criteria will be patients' clinical, biological and radiological medical data. The aim is to describe all risk factors for vascular phenotype in sclerodermic women with a previous pregnancy longer than 6 months.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Systemic Sclerosis</condition>
  <condition>Preeclampsia</condition>
  <condition>Vascular Complications</condition>
  <arm_group>
    <arm_group_label>cases</arm_group_label>
    <description>Cases will be defined as women with systemic sclerosis, specific vascular complications (digital ulcers, specific cardiac involvement of systemic sclerosis including pulmonary arterial hypertension, renal crisis) and with a previous pregnancy longer than 6 months before systemic sclerosis diagnosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <description>Controls will be defined as women with systemic sclerosis, no specific vascular complication and with a previous pregnancy longer than 6 months before systemic sclerosis diagnosis.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women with a diagnosis of systemic sclerosis according to EULAR 2013 diagnostic criteria
        AND with a history of pregnancy longer than 6 months (28 WG) before systemic sclerosis
        diagnosis

        followed in one of the French centers of expertise for systemic sclerosis will be offered
        to participate to the study during the annual follow-up consultation with her referring
        physician.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General:

        Women with a diagnosis of systemic sclerosis according to EULAR 2013 diagnostic criteria
        AND with a history of pregnancy longer than 6 months (28 weeks of gestation (WG)) before
        systemic sclerosis diagnosis.

          -  Specific:

        For the women of the &quot; case &quot; group :

        Women with vascular complications specific of systemic sclerosis (digital ulcers, specific
        cardiac involvement of systemic sclerosis including pulmonary arterial hypertension, renal
        crisis).

        For the women of the &quot; control &quot; group :

        Women with no vascular complications specific of systemic sclerosis.

        Non inclusion criteria :

          -  Refusal to participate to the study

          -  Minor women

          -  Women under tutorship

          -  Women with no pregnancy history or with a history of pregnancy(ies) below 6 months
             length.

        Exclusion Criteria:

          -  Women aged of less than 18 years

          -  Women on legal protection

          -  Women with no history of pregnancy of more than 6 months

          -  Women unable to fill out a questionnaire in French

          -  Women who refuse to participate to the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Claire DE MOREUIL</last_name>
    <phone>02 98 34 74 93</phone>
    <email>claire.demoreuil@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier Aumaitre</last_name>
      <email>oaumaitre@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sabine Berthier</last_name>
      <email>sabine.berthier@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric HACHULLA</last_name>
      <email>eric.hachulla@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne-Laure Fauchais</last_name>
      <email>alfauchais@orange.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian Agard</last_name>
      <email>christian.agard@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Viviane Queyrel</last_name>
      <email>queyrel-moranne.v@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alain Lescoat</last_name>
      <email>alain.lescoat@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gregory Pugnet</last_name>
      <email>pugnet.g@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Elisabeth Diot</last_name>
      <email>elisabeth.diot@univ-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Société française d'anesthésie et de réanimation (Sfar); Collège national des gynécologues et obstétriciens français (CNGOF); Société française de médecine périnatale (SFMP); Société française de néonatalogie (SFNN). [Multidisciplinary management of severe pre-eclampsia (PE). Experts' guidelines 2008. Société française d'anesthésie et de réanimation. Collège national des gynécologues et obstétriciens français. Société française de médecine périnatale. Société française de néonatalogie]. Ann Fr Anesth Reanim. 2009 Mar;28(3):275-81. doi: 10.1016/j.annfar.2009.02.015. Epub 2009 Mar 24. French.</citation>
    <PMID>19321292</PMID>
  </reference>
  <reference>
    <citation>Saucedo M, Deneux-Tharaux C, Bouvier-Colle MH; Le Comité national d’experts sur la mortalité maternelle. [Maternal mortality in France, 2007-2009]. J Gynecol Obstet Biol Reprod (Paris). 2013 Nov;42(7):613-27. doi: 10.1016/j.jgyn.2013.06.011. Epub 2013 Sep 13. French.</citation>
    <PMID>24035736</PMID>
  </reference>
  <reference>
    <citation>Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol. 1998 Aug;40(2):102-11.</citation>
    <PMID>9764352</PMID>
  </reference>
  <reference>
    <citation>Redman CW, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response--a review. Placenta. 2003 Apr;24 Suppl A:S21-7. Review.</citation>
    <PMID>12842410</PMID>
  </reference>
  <reference>
    <citation>Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med. 2008 Aug;14(8):855-62. doi: 10.1038/nm.1856. Epub 2008 Jul 27.</citation>
    <PMID>18660815</PMID>
  </reference>
  <reference>
    <citation>Herse F, Verlohren S, Wenzel K, Pape J, Muller DN, Modrow S, Wallukat G, Luft FC, Redman CW, Dechend R. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension. 2009 Feb;53(2):393-8. doi: 10.1161/HYPERTENSIONAHA.108.124115. Epub 2008 Dec 8.</citation>
    <PMID>19064815</PMID>
  </reference>
  <reference>
    <citation>Lim R, Acharya R, Delpachitra P, Hobson S, Sobey CG, Drummond GR, Wallace EM. Activin and NADPH-oxidase in preeclampsia: insights from in vitro and murine studies. Am J Obstet Gynecol. 2015 Jan;212(1):86.e1-12. doi: 10.1016/j.ajog.2014.07.021. Epub 2014 Jul 18.</citation>
    <PMID>25046804</PMID>
  </reference>
  <reference>
    <citation>Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989 Nov;161(5):1200-4.</citation>
    <PMID>2589440</PMID>
  </reference>
  <reference>
    <citation>Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007 Nov 10;335(7627):974. Epub 2007 Nov 1. Review.</citation>
    <PMID>17975258</PMID>
  </reference>
  <reference>
    <citation>Kamper-Jørgensen M, Gammill HS, Nelson JL. Preeclampsia and scleroderma: a prospective nationwide analysis. Acta Obstet Gynecol Scand. 2018 May;97(5):587-590. doi: 10.1111/aogs.13296. Epub 2018 Feb 8.</citation>
    <PMID>29344946</PMID>
  </reference>
  <reference>
    <citation>van Wyk L, van der Marel J, Schuerwegh AJ, Schouffoer AA, Voskuyl AE, Huizinga TW, Bianchi DW, Scherjon SA. Increased incidence of pregnancy complications in women who later develop scleroderma: a case control study. Arthritis Res Ther. 2011;13(6):R183. doi: 10.1186/ar3510. Epub 2011 Nov 4.</citation>
    <PMID>22053948</PMID>
  </reference>
  <reference>
    <citation>Englert H, Small-McMahon J, Davis K, O'Connor H, Chambers P, Brooks P. Systemic sclerosis prevalence and mortality in Sydney 1974-88. Aust N Z J Med. 1999 Feb;29(1):42-50.</citation>
    <PMID>10200812</PMID>
  </reference>
  <reference>
    <citation>Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, Buskila D, Dutz JP, Khostanteen I, Piper S, et al. Mortality in systemic sclerosis (scleroderma). Q J Med. 1992 Feb;82(298):139-48.</citation>
    <PMID>1620814</PMID>
  </reference>
  <reference>
    <citation>Simeón CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M, Lima J, Vaqué J, Vilardell M. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford). 2003 Jan;42(1):71-5.</citation>
    <PMID>12509616</PMID>
  </reference>
  <reference>
    <citation>Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol. 1998 Jul;37(7):750-5.</citation>
    <PMID>9714351</PMID>
  </reference>
  <reference>
    <citation>Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis. 1998 Nov;57(11):682-6.</citation>
    <PMID>9924211</PMID>
  </reference>
  <reference>
    <citation>LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988 Feb;15(2):202-5.</citation>
    <PMID>3361530</PMID>
  </reference>
  <reference>
    <citation>van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013 Nov;65(11):2737-47. doi: 10.1002/art.38098. Epub 2013 Oct 3.</citation>
    <PMID>24122180</PMID>
  </reference>
  <reference>
    <citation>Riemekasten G, Philippe A, Näther M, Slowinski T, Müller DN, Heidecke H, Matucci-Cerinic M, Czirják L, Lukitsch I, Becker M, Kill A, van Laar JM, Catar R, Luft FC, Burmester GR, Hegner B, Dragun D. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis. 2011 Mar;70(3):530-6. doi: 10.1136/ard.2010.135772. Epub 2010 Nov 15.</citation>
    <PMID>21081526</PMID>
  </reference>
  <reference>
    <citation>Walther T, Wallukat G, Jank A, Bartel S, Schultheiss HP, Faber R, Stepan H. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension. 2005 Dec;46(6):1275-9. Epub 2005 Oct 31.</citation>
    <PMID>16260641</PMID>
  </reference>
  <reference>
    <citation>Nelson JL, Furst DE, Maloney S, Gooley T, Evans PC, Smith A, Bean MA, Ober C, Bianchi DW. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet. 1998 Feb 21;351(9102):559-62.</citation>
    <PMID>9492775</PMID>
  </reference>
  <reference>
    <citation>Allanore Y, Distler O, Matucci-Cerinic M, Denton CP. Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis. Arthritis Rheumatol. 2018 Feb;70(2):162-170. doi: 10.1002/art.40377. Epub 2018 Jan 22. Review.</citation>
    <PMID>29145709</PMID>
  </reference>
  <reference>
    <citation>Lescoat A, Yelnik CM, Coiffier G, Wargny M, Lamotte C, Cazalets C, Belhomme N, Ballerie A, Hatron PY, Launay D, Perdriger A, Sobanski V, Hachulla E, Jégo P. Ulnar Artery Occlusion and Severity Markers of Vasculopathy in Systemic Sclerosis: A Multicenter Cross-Sectional Study. Arthritis Rheumatol. 2019 Jun;71(6):983-990. doi: 10.1002/art.40799. Epub 2019 Apr 29.</citation>
    <PMID>30552835</PMID>
  </reference>
  <reference>
    <citation>Diehl CL, Brost BC, Hogan MC, Elesber AA, Offord KP, Turner ST, Garovic VD. Preeclampsia as a risk factor for cardiovascular disease later in life: validation of a preeclampsia questionnaire. Am J Obstet Gynecol. 2008 May;198(5):e11-3. doi: 10.1016/j.ajog.2007.09.038. Epub 2008 Feb 1.</citation>
    <PMID>18241822</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>systemic sclerosis</keyword>
  <keyword>vascular phenotype</keyword>
  <keyword>pre-eclampsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning two year and ending five years following the end study</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

